GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.<\/p>\n
Details for the panel are as follows:<\/p>\n
About Novavax<\/p>\n
Novavax, Inc. (NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.<\/p>\n
For more information, visit http:\/\/www.novavax.com<\/a> and connect with us on Twitter and LinkedIn.<\/p>\n Contacts:<\/p>\n InvestorsNovavax, Inc. Erika Trahanir@novavax.com240<\/a>-268-2022<\/p>\n WestwickeJohn Woolfordjohn.woolford@westwicke.com443<\/a>-213-0506<\/p>\n MediaBrandzone\/KOGS CommunicationEdna Kaplankaplan@kogspr.com617<\/a>-974-8659<\/p>\n <\/p>\n Read this article:<\/p>\n Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. Continue reading